955 completed, 103 terminated, 72 unknown, 55 withdrawn. 1297 Phase 2, 226 Phase 1, 96 Phase 3.
Follow Sexually Transmitted Diseases: new trials by email Literature Review of Sexually Transmitted Diseases trials Research Report on Sexually Transmitted Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs ATRN-119, Stereotactic Body Radiation Therapy (SBRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 35 | 2027-01-31 | 2026-10-27 |
| Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections | Phase 1 / Phase 2 | Withdrawn | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 2026-12-31 | 2026-08-17 | |
| DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg DOR/ISL - HIV-1, HIV Infection | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 45 | 2026-12-23 | 2026-10-07 |
| Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml - HIV - Human Immunodeficiency Virus | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 36 | 2026-12-01 | 2026-10-01 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support - Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV) | Phase 2 | Recruiting | Nicky Mehtani, MD, MPH | 30 | 2026-12-01 | 2026-11-09 |
| A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size Ixazomib 4 mg, Placebo - HIV (Human Immunodeficiency Virus) | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 45 | 2026-11-23 | 2026-10-19 |
| Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) PRGN-2012, Bevacizumab - Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV) | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 50 | 2026-11-15 | 2026-11-10 |
| Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine 10vHPV, Gardasil9 - Human Papillomavirus Infection | Phase 1 / Phase 2 | Not yet recruiting | Serum Institute of India Pvt. Ltd. | 72 | 2026-11-01 | 2026-11-06 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) Isoniazid, Rifampin, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 900 | 2026-10-30 | 2026-08-19 |
| A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY) VH4011499, CAB, DTG/3TC - HIV Infections | Phase 2 | Not yet recruiting | ViiV Healthcare | 200 | 2026-10-19 | 2026-09-11 |
| A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Recruiting | University of Maryland, Baltimore | 132 | 2026-10-19 | 2026-11-06 |
| Baricitinib Curative Repression of HIV-1 Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg - HIV Infection, HIV | Phase 2 | Not yet recruiting | Emory University | 35 | 2026-10-01 | 2026-08-17 |
| Multicentre Study Evaluating the Efficacy of a 7-day Course of Doxycycline for the Treatment of Asymptomatic Anal Lymphogranuloma Venereum. Doxycline - Lymphogranuloma Venereum, no Anorectal Symptoms | Phase 2 | Not yet recruiting | University Hospital, Bordeaux | 120 | 2026-09-01 | 2026-08-17 |
| Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya 5% 5-fluorouracil Topical Cream, Placebo Cream - HIV Infections, HPV Infection | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-09-01 | 2026-08-27 |
| Safety and Immunogenicity of HPV Vaccine in HIV-infected HPV vaccination - HIV-infected Individuals | Phase 1 / Phase 2 | Not yet recruiting | Beijing 302 Hospital | 80 | 2026-09-01 | 2026-09-01 |
| Precision Microbiota Interventions for Senoreduction Trial Limosilactobacillus reuteri, Blueberry extract - HIV Infections, Alcohol Drinking | Phase 1 / Phase 2 | Recruiting | Louisiana State University Health Sciences Center in New Orleans | 160 | 2026-09-01 | 2026-10-29 |
| Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment Multiple therapeutic interventions - HIV - Human Immunodeficiency Virus | Phase 2 | Recruiting | Federal University of São Paulo | 70 | 2026-08-01 | 2026-10-29 |
| Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel Geniwa gel, Placebo gel - HPV (Human Papillomavirus)-Associated, Genital Warts | Phase 2 | Recruiting | KTH Biopharma | 70 | 2026-07-16 | 2026-10-20 |
| Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals Maraviroc, Dolutegravir, Dendritic Cell Vaccine - Hiv, HIV I Infection | Phase 2 | Recruiting | Federal University of São Paulo | 70 | 2026-07-15 | 2026-08-19 |
Showing 20 of 1297. Sign in to see all of them.
HIV Infections (919) · Acquired Immunodeficiency Syndrome (418) · Papillomavirus Infections (91) · AIDS-Related Complex (56) · Infections (35) · Tuberculosis (31) · Hepatitis C (30) · Sarcoma, Kaposi (27) · Condylomata Acuminata (25) · HIV Seropositivity (25) · AIDS-Related Opportunistic Infections (24) · Uterine Cervical Neoplasms (24) · Herpes Genitalis (16) · Substance-Related Disorders (16)
Genital Diseases (1297) · Urogenital Diseases (1297) · Communicable Diseases (1294) · Infections (1262) · Sexually Transmitted Diseases, Viral (1258) · Virus Diseases (1253) · Blood-Borne Infections (1149) · Immune System Diseases (1146) · RNA Virus Infections (1146) · Lentivirus Infections (1145) · Retroviridae Infections (1145) · Immunologic Deficiency Syndromes (1142) · Slow Virus Diseases (434) · HIV Infections (230)
Ritonavir (81) · Zidovudine (79) · Lamivudine (66) · Tenofovir (56) · Didanosine (49) · Stavudine (45) · efavirenz (45) · Emtricitabine (40) · Lopinavir (34) · Indinavir (32) · Saquinavir (30) · Nevirapine (29) · abacavir (28) · Raltegravir Potassium (27) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (26)
National Institute of Allergy and Infectious Diseases (NIAID) (283) · ViiV Healthcare (41) · Merck Sharp & Dohme LLC (33) · National Cancer Institute (NCI) (30) · French National Agency for Research on AIDS and Viral Hepatitis (25) · GlaxoSmithKline (22) · ANRS, Emerging Infectious Diseases (21) · Centers for Disease Control and Prevention (20) · Gilead Sciences (18) · Boehringer Ingelheim (15) · Tibotec Pharmaceuticals, Ireland (15) · National Center for Complementary and Integrative Health (NCCIH) (13) · The HIV Netherlands Australia Thailand Research Collaboration (13) · Glaxo Wellcome (11) · Hoffmann-La Roche (11)
United States (774) · South Africa (116) · Puerto Rico (113) · France (88) · Canada (79) · Spain (67) · Thailand (65) · Germany (55) · United Kingdom (48) · Brazil (46) · Argentina (45) · Uganda (40) · Italy (38) · Australia (31) · China (30)
Kiat Ruxrungtham, MD (7) · Corey L (5) · Scott Hammer (5) · Sybil Hosek, PhD (5) · Fischl MA (4) · Jeffrey H Herbst, PhD (4) · Priscilla Hsue, MD (4)
PMID 40190112, PMID 41276263, PMID 34895272, PMID 25424918, PMID 34817414, PMID 40342086, PMID 40655875, PMID 18832244, PMID 18832245, PMID 19118378, PMID 19191652, PMID 20672447, PMID 20703158, PMID 22336878, PMID 24391139, PMID 24419064, PMID 25296098, PMID 25820067, PMID 26902761, PMID 27566633, PMID 31042791, PMID 31179503, PMID 31464859, PMID 31824943, PMID 32827835, PMID 33493795, PMID 33587505, PMID 33587510, PMID 33730454, PMID 34213402, PMID 34343443, PMID 34652287, PMID 34996113, PMID 35358290, PMID 37351709, PMID 38097552, PMID 40698814, PMID 42444466, PMID 42731017, PMID 10659875, PMID 11840078, PMID 11919489, PMID 11980557, PMID 12232843, PMID 12559647, PMID 12631091, PMID 12866833, PMID 14676028, PMID 15056863, PMID 15060509
2008 (8), U01CA121947 (6), UM1CA121947 (6), 2004 (5), 2009 (5), 2023 (5), U01AI068636 (5), 2014 (4), 2005 (3), 2019 (3), 2025 (3), U01AI068632 (3), 2015 (2), 2016 (2), 2018 (2)